Depomed Inc: Shareholders Board Members Managers and Company Profile | US2499081048

Business description: Depomed Inc

Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Companyâ€™s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).

Sales by Activity: Depomed Inc

Fiscal Period: December	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)
Pharmaceuticals	108M	111M	156M	152M	125M

See all business segments

Geographical breakdown of sales: Depomed Inc

Fiscal Period: December	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)
United States	108M	111M	156M	152M	125M

See all geographic segments

Executive Committee: Depomed Inc

Manager	Title	Age	Since
Mark Reisenauer CEO	Chief Executive Officer	61	2025-10-27
Ajay Patel DFI	Director of Finance/CFO	42	2023-11-07
Paul Schwichtenberg DFI	Director of Finance/CFO	55	2021-03-10
Molly Dir ADM	Chief Administrative Officer	-	-
Howard Franklin CTO	Chief Tech/Sci/R&D Officer	-	2023-03-05

See DEPOMED INC governance

Composition of the Board of Directors: Depomed Inc

Director	Title	Age	Since
William McKee BRD	Director/Board Member	64	2017-02-28
Heather Mason CHM	Chairman	65	2024-11-06
Sravan Emany BRD	Director/Board Member	48	2023-11-13
Sigurd Kirk BRD	Director/Board Member	59	2024-04-02
David Stark BRD	Director/Board Member	57	2024-11-06
Mark Reisenauer BRD	Director/Board Member	61	2025-01-01

Composition of the Board of Directors

Shareholders: Depomed Inc

Name	Equities	%	Valuation
Nantahala Capital Management LLC 9.153 %	587,335	9.153 %	7 M $
Vanguard Fiduciary Trust Co. 4.632 %	297,247	4.632 %	3 M $
Opaleye Management, Inc. 4.441 %	285,000	4.441 %	3 M $
Renaissance Technologies LLC 2.972 %	190,697	2.972 %	2 M $
Edgewood Management LLC 1.676 %	107,518	1.676 %	1 M $

List of DEPOMED INC shareholders

Company details: Depomed Inc

Assertio Holdings, Inc.

100 South Saunders Road

60045, Lake Forest

+

http://www.assertiotx.com

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ELI LILLY AND COMPANY	-0.70%	-0.63%	+20.68%	+217.87%	895B
JOHNSON & JOHNSON	+0.46%	-1.23%	+45.32%	+60.75%	587B
ABBVIE INC.	-0.19%	-2.93%	+4.78%	+51.63%	401B
ROCHE HOLDING AG	+0.84%	-5.68%	+9.04%	+27.14%	345B
NOVARTIS AG	-2.63%	-3.48%	+20.34%	+63.50%	300B
ASTRAZENECA PLC	+1.47%	-1.86%	+23.75%	+36.98%	306B
MERCK & CO., INC.	-0.02%	-2.29%	+22.95%	+8.73%	289B
AMGEN INC.	-0.41%	-0.42%	+14.68%	+64.76%	202B
GILEAD SCIENCES, INC.	+1.32%	+0.49%	+26.75%	+86.87%	184B
Average	+0.02%	-2.00%	+20.92%	+68.69%	390.05B
Weighted average by Cap.	-0.09%	-1.91%	+22.24%	+91.92%